Captrust Financial Advisors Aim Immuno Tech Inc. Transaction History
Captrust Financial Advisors
- $33 Billion
- Q3 2024
A detailed history of Captrust Financial Advisors transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 20,000 shares of AIM stock, worth $4,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$4,200
Previous $7,000
28.57%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$909,3000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$417,6270.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$146,6360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$97,4430.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$96,1310.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $10.1M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...